1. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
- Author
-
Sajja AP, Dey AK, Guha A, Elnabawi Y, Joshi AA, and Kalra A
- Subjects
- Biomarkers blood, Blood Glucose metabolism, Cardiovascular Diseases blood, Cardiovascular Diseases diagnosis, Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 mortality, Humans, Incretins adverse effects, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Treatment Outcome, Blood Glucose drug effects, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide-1 Receptor agonists, Incretins therapeutic use, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
There is a growing body of evidence that diabetes represents a significant and largely modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the risk of CVD-with CVD accounting for 2 of every 3 deaths in patients with diabetes. It is suggested that once patients with diabetes develop clinical coronary disease, they have a grim prognosis. In 2008, the Food and Drug Association mandated the evidence of CV safety in any new diabetic therapy, leading to a multitude of large CV outcome trials to assess CV risk from these medications. However, several of these outcome trials with novel antidiabetic therapies have demonstrated not only safety but a clear and definite CV advantage in patients with type 2 diabetes. In this review, we discuss 2 relatively newer classes of diabetic drugs, sodium glucose cotransport 2 inhibitors and glucagon-like peptide 1 agonists, evaluate their efficacy in improving CV outcomes, and discuss the future of CV prevention with these agents.
- Published
- 2019
- Full Text
- View/download PDF